Circulating Tumor DNA in Soft Tissue Sarcoma
ConditionSoft Tissue Sarcoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Health Network, Toronto
About this trial
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA). When tumor cells are damaged or die, DNA from the tumor cells are released into the blood stream as the cells break down. This is called circulating tumor DNA. Circulating tumor DNA is an important biomarker that may be used in cancer detection, prediction of treatment response, and disease monitoring.
Eligibility criteria
Qualifiers
Patients must have histologically confirmed high-risk extremity or retroperitoneal liposarcoma, leiomyosarcoma and undifferentiated pleomorphic sarcoma.
Patients must have archival tissue from the diagnostic biopsy available.
Deemed appropriate for preoperative or postoperative radiotherapy and curative surgery following patient assessment by radiation oncologist and surgical oncologist.
Age 18 years or older.
Disqualifiers
Patients with benign histology
Patients with prior malignancy within previous 5 years or concurrent malignancy other than adequately treated basal cell carcinoma of skin or carcinoma in-situ of cervix.
Patients with planned neo-adjuvant chemotherapy.
Patients with regional nodal disease or unequivocal metastases
Trial design
Treatments tested in this trial
- Archival tumor tissue collection and blood draws
Treatment groups
40 Participants
are divided into 1 treatment groupLocations
1Princess Margaret Cancer CentreM5G 2M9, TorontoOntario, Canada
Sponsors and collaborators
University Health Network, Toronto
Lead sponsor
Mount Sinai Hospital, Canada
Collaborator
The Hospital for Sick Children
Collaborator
Source ClinicalTrials.gov